Skip to main content

Table 3 Annual cost in euros per patient and per bDMARD

From: Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort

bDMARD

Standard care group n (%)

Annual cost per patient in euros (€) for the standard care group

Dose reduction group n (%)

Annual cost per patient in euros (€) for the dose reduction group

ABA

11 (5.7)

12,979

11 (7.9)

8643.5

ADA

14 (7.3)

12,525

28 (20.0)

7175.03

CZP

5 (2.6)

11,740.2

0 (0)

Not available

ETN

29 (15.1)

9328.6

30 (21.4)

5580.04

GOL

19 (9.9)

12,703.08

3 (2.1)

Not available

IFX

68 (35.41)

7290

28 (20)

6146.5

RTX

17 (8.85)

8784

18 (12.85)

4675.03

TOC

29 (15.1)

12,773.7

22 (15.71)

9487.7

 

192

 

140